Cargando…

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling

PURPOSE: Menopause is associated with an increased risk of estrogen receptor-positive (ER +) breast cancer. To characterize the metabolic shifts associated with reduced estrogen bioavailability on breast tissue, metabolomics was performed from ovary-intact and ovariectomized (OVX) female non-human p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnone, Alana A., Cline, J. Mark, Soto-Pantoja, David R., Cook, Katherine L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557185/ https://www.ncbi.nlm.nih.gov/pubmed/34448090 http://dx.doi.org/10.1007/s10549-021-06354-w

Ejemplares similares

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Tie2-Cre–Induced Inactivation of Non-Nuclear Estrogen Receptor-α Signaling Abrogates Estrogen Protection Against Vascular Injury
por: Liu, Pang-Yen, et al.
Publicado: (2022)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy
por: Fukuma, Nobuaki, et al.
Publicado: (2020)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

In Pursuit of Understanding the Role of Estrogens in Regulating Cardiac Structure and Function
por: Villarreal, Francisco
Publicado: (2020)

The Effect of Estrogen on Intracellular Ca(2+) and Na(+) Regulation in Heart Failure
por: Firth, Jahn M., et al.
Publicado: (2020)

Blockade of Estrogen Action Upregulates Estrogen Receptor-α mRNA in the Fetal Brain
por: Schaub, Christine E., et al.
Publicado: (2009)

Aberrant insular cortex connectivity in abstinent alcohol‐dependent rats is reversed by dopamine D3 receptor blockade
por: Scuppa, Giulia, et al.
Publicado: (2019)

Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer
por: Bhardwaj, Anjana, et al.
Publicado: (2021)

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
por: Garner, Fiona, et al.
Publicado: (2015)

Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells
por: Wang, Lu, et al.
Publicado: (2022)

Less Carcinogenic Chlorinated Estrogens Applicable to Hormone Replacement Therapy
por: Okamoto, Yoshinori, et al.
Publicado: (2021)

Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes.
por: Jørgensen, M, et al.
Publicado: (2000)

Sex differences in binge‐like EtOH drinking, corticotropin‐releasing hormone and corticosterone: effects of β‐endorphin
por: Nentwig, Todd B., et al.
Publicado: (2018)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
por: Anderson, Richard A., et al.
Publicado: (2022)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

Central carbon metabolism in the progression of mammary carcinoma
por: Richardson, Adam D., et al.
Publicado: (2007)

Endogenous estrogens—breast cancer and chemoprevention
por: Starek-Świechowicz, Beata, et al.
Publicado: (2021)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
por: Fan, Yu, et al.
Publicado: (2022)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway
por: Zhou, Jiabin, et al.
Publicado: (2019)

Could Perimenopausal Estrogen Prevent Breast Cancer? Exploring the Differential Effects of Estrogen-Only Versus Combined Hormone Replacement Therapy
por: Manyonda, Isaac, et al.
Publicado: (2022)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines
por: Xu, Xia, et al.
Publicado: (2012)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Associations Between Endogenous Estrogen, Postmenopausal Hormone Therapy, and Cognitive Changes in Older Women
por: Espeland, Mark, et al.
Publicado: (2021)

Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin combination hormone therapy among women in the United States: a multidatabase cohort study
por: Hoffman, Sarah R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cc0nl3rikuiubhvuc16n1oujfk